Effects of the Long-Acting Human Glucagon-Like Peptide-1 Analog Liraglutide on β-Cell Function in Normal Living Conditions

iraglutide is a long-acting glucagonlike peptide (GLP)-1 analog, which exerts its glucose-lowering action through multiple mechanisms (1).One important feature of liraglutide is its ability to enhance ␤-cell function.The effects on ␤-cell function have been demonstrated using standardized ␤-cell function tests based on intravenous glucose administration (2-4).However, these studies may not reflect the modes of action of liraglutide during normal living.To assess the effects of liraglutide on ␤-cell function in normal living, we have used a validated ␤-cell model to analyze 24-h triple-meal experiments. RESEARCH DESIGN AND METHODS-This study includes data used for a different analysis in a previous publication (3), where the experimental protocol, approved by the local ethics committee and performed in accordance with the Helsinki Declaration, was described in detail.Thirteen type 2 diabetic patients (five women and eight men) were examined.Their mean Ϯ SD age was 56.4 Ϯ 9.2 years, BMI was 31.2Ϯ 3.6 kg/m 2 , last measured A1C before inclusion was 7.3 Ϯ 0.4% (normal range Ͻ6.4%), and the duration of diabetes was 3.0 Ϯ 2.6 years.The study is a randomized, doubleblind, placebo-controlled, crossover